CN1554426A - Oral medicine for treating child restless syndrome - Google Patents
Oral medicine for treating child restless syndrome Download PDFInfo
- Publication number
- CN1554426A CN1554426A CNA2003101222237A CN200310122223A CN1554426A CN 1554426 A CN1554426 A CN 1554426A CN A2003101222237 A CNA2003101222237 A CN A2003101222237A CN 200310122223 A CN200310122223 A CN 200310122223A CN 1554426 A CN1554426 A CN 1554426A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- present
- treatment
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The orally taken medicine for treating children's hyperkinesia is prepared with 7 kinds of Chinese medicinal materials, including schisandra, common jujube seed, white peony root, gastrodia tuber, buffalo horn, etc. in certain proportion. Initial clinical test shows that the orally taken medicine has obvious curative effect similar to that of Methylphenidate but less side effect. It may be further tested clinically.
Description
Technical field
The invention belongs to the medicinal preparation technical field of the product that contains raw material or itself and not clear structure, be specifically related to derive from the material of plant.
Background technology
Childhood hyperkinetic syndrome is that a kind of common children's behavior is unusual, claims Cerebral function slight maladjustment or slight cerebral function disorder syndrome or attention deficit hyperactivity disorder again.Foreign data report prevalence is about 5～10%, and domestic to think that also school age population is sent out the patient quite a lot of, accounts for all pupils' 1～10%, and boy's prevalence is greater than girl, and it is more that the premature infant suffers from the patient.Childhood hyperkinetic syndrome is the difficult problem that at present domestic and international medical circle is not captured as yet.
The medicine commonly used clinically at present for childhood hyperkinetic syndrome has:
Methylphenidate: this medicine is adapted to the child more than 6 years old.Common adverse effect has appetite to descend or anorexia, is difficult for falling asleep, and uneasiness, dizzy and nervous anxiety can appear in using dosage when big.
Dextro-amphetamine: be adapted to the child more than 3 years old.Side effect is for insomnia, dizzy, inappetence and lose weight, and influential to growth promoter.
Azoxodone: this product is a revitalizer, is adapted to the child more than 6 years old.This medicine has the liver delayed hypersensitivity reaction.
In addition, also have medicines such as caffeine, imipramine, chlorpromazine.
Said medicine treatment childhood hyperkinetic syndrome all has certain curative effect, but the course of treatment is longer, and the lighter took medicine 6～12 months, and heavy person will take medicine 3～5 years, adhered to for a long time taking medicine, and toxic and side effects is in various degree all arranged.
Summary of the invention
Technical problem to be solved by this invention is to overcome the shortcoming of said medicine, the oral drugs of the treatment childhood hyperkinetic syndrome that provide a kind of evident in efficacy, short treating period, has no side effect.
It is with the following materials of weight proportions Peroral solid dosage form medicament made of formulation method routinely to solve the problems of the technologies described above the technical scheme that adopted:
6～18 parts of Fructus Schisandrae Chinensis
5～30 parts of Semen Ziziphi Spinosaes
6～18 parts of the Radix Paeoniae Albas
5～15 parts in Rhizoma Gastrodiae
1～6 part of Cornu Bubali
6～15 parts of Radix Curcumaes
1～6 part in Radix Glycyrrhizae
The preferred weight proportioning of preparation medicine of the present invention is:
8～15 parts of Fructus Schisandrae Chinensis
10～25 parts of Semen Ziziphi Spinosaes
8～15 parts of the Radix Paeoniae Albas
5～12 parts in Rhizoma Gastrodiae
2～5 parts of Cornu Bubalis
8～12 parts of Radix Curcumaes
1～5 part in Radix Glycyrrhizae
The optimum weight proportioning of preparation medicine of the present invention is:
10 parts of Fructus Schisandrae Chinensis
15 parts of Semen Ziziphi Spinosaes
12 parts of the Radix Paeoniae Albas
8 parts in Rhizoma Gastrodiae
4 parts of Cornu Bubalis
10 parts of Radix Curcumaes
3 parts in Radix Glycyrrhizae
The Peroral solid dosage form medicament that above-mentioned each component is made according to a conventional method is said powder or capsule or a tablet on the galenic pharmacy.
The preparation technology of drug powder of the present invention is as follows:
1, with Radix Curcumae, Rhizoma Gastrodiae, Fructus Schisandrae Chinensis, Cornu Bubali four Chinese medicine, be ground into 100 order fineness, standby.
2, the Radix Paeoniae Alba, Semen Ziziphi Spinosae, Radix Glycyrrhizae are decocted with water three times, add 10 times of water gagings for the first time and decocted 2 hours, second and third time adds 8 times of water gagings respectively and decocted 1 hour, decocting liquid merges, leave standstill, filter, filtrate decompression is condensed into the extractum that relative density is 1.20～1.25 (80 ℃).
3, the fine powder with 1 preparation joins in the extractum of 2 preparations, stir with blender, it is fully mixed, and 60 ℃ of oven dry are ground into 100 order fineness, add the dextrin excipient, to every gram drug powder of the present invention, contain crude drug in whole 0.496g, fully mix, add alcohol granulation then, granulate, 50 ℃ of dryings.
4, by the quality standard check of powder of the present invention, in the plastic bag of packing into behind ultraviolet disinfection, encapsulation is put in storage.
The preparation technology of medicine capsule of the present invention is as follows:
1, with Radix Curcumae, Rhizoma Gastrodiae, Fructus Schisandrae Chinensis, Cornu Bubali four Chinese medicine, be ground into 100 order fineness, standby.
2, the Radix Paeoniae Alba, Semen Ziziphi Spinosae, Radix Glycyrrhizae are decocted with water three times, add 10 times of water gagings for the first time and decocted 2 hours, second and third time adds 8 times of water gagings respectively and decocted 1 hour, decocting liquid merges, leave standstill, filter, filtrate decompression is condensed into the extractum of relative density 1.20～1.25 (80 ℃).
3, the fine powder with 1 preparation joins in the extractum of 2 preparations, stir with blender, it is fully mixed, 60 ℃ of oven dry are ground into 100 order fineness, add the starch excipient, to every gram medicine capsule of the present invention, contain crude drug in whole 1.55g, fully mix, add alcohol granulation then, 50 ℃ of dryings.
4,, in after the ultraviolet disinfection sterilization, incapsulating, make capsule of the present invention by the quality standard check of medicine capsule of the present invention.Proportioning raw materials that capsule is used and preparation technology press galenic pharmacy capsule proportioning raw materials preparation technology routinely and make.
The preparation technology of medicinal tablet of the present invention is as follows:
The proportioning of the raw material of Chinese medicine that the proportioning of the raw material of Chinese medicine that medicinal tablet of the present invention is used and the extraction of active ingredient and medicine capsule of the present invention are used and the extraction of active ingredient are identical, and used adjuvant and consumption are undertaken by the conventional preparation technology of tablet.Every heavy 0.4g, every gram contains crude drug in whole 1.24g.
Medicament capsule of the present invention is tested through 120 example initial stage clinic observation, result of the test treatment group produce effects 31 examples (51.67%), and effective 18 examples (30%), invalid 11 examples (18.33%), total effective rate is 81.67%.Matched group produce effects 37 examples (61.67%), effective 14 examples (23.33%), invalid 9 examples (15%), total effective rate is 85%.Two groups of curative effect differences do not have significance meaning (Ridit analyzes, t=0.672, P＞0.05).Medicine of the present invention is a kind of active drug of treatment childhood hyperkinetic syndrome, and curative effect and methylphenidate are suitable, and side effect is little, further expanding test clinically.
The specific embodiment
The present invention is described in more detail below in conjunction with embodiment, but the invention is not restricted to these embodiment.
Embodiment 1
With production powder product of the present invention 1000g is that used raw material of example and proportioning thereof are:
Fructus Schisandrae Chinensis 80g
Semen Ziziphi Spinosae 120g
Radix Paeoniae Alba 96g
Rhizoma Gastrodiae 64g
Cornu Bubali 32g
Radix Curcumae 80g
Radix Glycyrrhizae 24g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of powder of the present invention.The heavy 5g of every bag, every gram contains crude drug in whole 0.496g.
With 1000 of production capsule products of the present invention is that used raw material of example and proportioning thereof are:
Fructus Schisandrae Chinensis 100g
Semen Ziziphi Spinosae 150g
Radix Paeoniae Alba 120g
Rhizoma Gastrodiae 80g
Cornu Bubali 40g
Radix Curcumae 100g
Radix Glycyrrhizae 30g
Starch adds to 400g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.4g, every gram contains crude drug in whole 1.55g.
In its proportioning, the weight portion of each component of raw material of Chinese medicine is:
10 parts of Fructus Schisandrae Chinensis
15 parts of Semen Ziziphi Spinosaes
12 parts of the Radix Paeoniae Albas
8 parts in Rhizoma Gastrodiae
4 parts of Cornu Bubalis
10 parts of Radix Curcumaes
3 parts in Radix Glycyrrhizae
Embodiment 2
With production powder product of the present invention 1000g is that used raw material of example and proportioning thereof are:
Fructus Schisandrae Chinensis 99.20g
Semen Ziziphi Spinosae 82.67g
Radix Paeoniae Alba 99.20g
Rhizoma Gastrodiae 82.67g
Cornu Bubali 16.53g
Radix Curcumae 99.20g
Radix Glycyrrhizae 16.53g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of powder of the present invention.The heavy 5g of every bag, every gram contains crude drug in whole 0.496g.
With 1000 of production capsule products of the present invention is that used raw material of example and proportioning thereof are:
Fructus Schisandrae Chinensis 124g
Semen Ziziphi Spinosae 103.33g
Radix Paeoniae Alba 124g
Rhizoma Gastrodiae 103.33g
Cornu Bubali 20.67g
Radix Curcumae 124g
Radix Glycyrrhizae 20.67g
Starch adds to 400g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.4g, every gram contains crude drug in whole 1.55g.
In its proportioning, the weight portion of each component of raw material of Chinese medicine is:
6 parts of Fructus Schisandrae Chinensis
5 parts of Semen Ziziphi Spinosaes
6 parts of the Radix Paeoniae Albas
5 parts in Rhizoma Gastrodiae
1 part of Cornu Bubali
6 parts of Radix Curcumaes
1 part in Radix Glycyrrhizae
Embodiment 3
With production powder product of the present invention 1000g is that used raw material of example and proportioning thereof are:
Fructus Schisandrae Chinensis 82.67g
Semen Ziziphi Spinosae 137.78g
Radix Paeoniae Alba 82.67g
Rhizoma Gastrodiae 68.89g
Cornu Bubali 27.56g
Radix Curcumae 68.89g
Radix Glycyrrhizae 27.56g
Dextrin adds to 1000g
Its preparation technology is undertaken by the preparation technology of powder of the present invention.The heavy 5g of every bag, every gram contains crude drug in whole 0.496g.
With 1000 of production capsule products of the present invention is that used raw material of example and proportioning thereof are:
Fructus Schisandrae Chinensis 103.33g
Semen Ziziphi Spinosae 172.22g
Radix Paeoniae Alba 103.33g
Rhizoma Gastrodiae 86.11g
Cornu Bubali 34.44g
Radix Curcumae 86.11g
Radix Glycyrrhizae 34.44g
Starch adds to 400g
Its preparation technology is undertaken by the preparation technology of capsule of the present invention.Every heavy 0.4g, every gram contains crude drug in whole 1.55g.
In its proportioning, the weight portion of each component of raw material of Chinese medicine is:
18 parts of Fructus Schisandrae Chinensis
30 parts of Semen Ziziphi Spinosaes
18 parts of the Radix Paeoniae Albas
15 parts in Rhizoma Gastrodiae
6 parts of Cornu Bubalis
15 parts of Radix Curcumaes
6 parts in Radix Glycyrrhizae
More than provided the proportioning embodiment of powder of the present invention and the used raw material of Chinese medicine of capsule, the proportioning of the used raw material of Chinese medicine of same applicable preparation identical weight medicinal tablet of the present invention, prepare the selection of the used adjuvant of medicinal tablet of the present invention and the proportioning and the preparation technology of adjuvant, the preparation technology of preparation method tablet carries out routinely.Every heavy 0.4g, every gram contains crude drug in whole 1.24g.
In order to verify the therapeutic effect of medicine of the present invention to childhood hyperkinetic syndrome, the applicant will adopt medicine of the present invention (name is called quiet handsome health during test) the capsule consignment test unit of the embodiment of the invention 1 proportioning preparation to carry out 120 example initial stage clinical observation tests, and test situation is as follows:
One, clinical data
Observing case is and derives from January, the 2002～2002 year December infant at this hospital admission.Meet the childhood hyperkinetic syndrome diagnostic criteria of " Chinese mental sickness classification schemes and diagnostic criteria "-CCMD--R (the 2nd edition revised edition).Get rid of mental retardation, child psychosis, anxiety state, conduct disorder or nervous system disease and naughty child, totally 120 examples.Be divided into two groups by randomly assigne, treatment by Chinese herbs group 60 examples, wherein male 32 examples, women 28 examples, 7～12 years old age, average 9.1 ± 1.4 years old; The course of disease 6～48 months.Methylphenidate matched group 60 examples, male 37 examples, women 23 examples, 7～13 years old age, average 9.0 ± 1.6 years old, the course of disease 6～60 months.Two groups of above every comparing differences there are no significant difference (P＞0.05).
Two, diagnostic criteria
By the childhood hyperkinetic syndrome diagnostic criteria diagnosis of " Chinese mental sickness classification schemes and diagnostic criteria "-CCMD--R (the 2nd edition revised edition), get rid of mental retardation, child psychosis, anxiety state, conduct disorder or nervous system disease and naughty child.
Three, Therapeutic Method
The treatment group: oral medicament capsule of the present invention, every day 3 times, taking medicine before meal usefulness, below 2 years old each 2,2～3 years old each 3,3～7 years old each 4, more than 7 years old each 5～6.
Matched group: oral methylphenidate, every day, 10～30mg divided morning, p.prand oral.
Observation index: treating observing time was 12 weeks, marking with many moving index scales (Conners), father and mother's SQ (Achenbach), clinical global impression scale (CGI), side reaction scale (Tess) per 2 weekends in before the treatment and treatment back, carries out before routine blood test, liver function, electroencephalogram, the IQ treatment simultaneously and treatment check at 12 weekends.
Four, criterion of therapeutical effect
This group case is with reference to the branch rate that the subtracts evaluation curative effect of clinical efficacy standard of working out in " up-to-date domestic and international disease treatment standard " and Conners isodose chart.
Produce effects: cardinal symptom disappears or significantly improves, and how moving index scoring reduces more than 80%, and school grade improves more than 10 minutes.
Effectively: cardinal symptom is improved, and how moving index scoring reduces more than 50%, and school grade improves below 10 minutes.
Invalid: no change after the medication.
Five, therapeutic outcome
1, therapeutic outcome
Reach treatment many moving index total points at 12 weekends, behavior total points before two groups of treatments relatively, result of the test sees Table 1.
2, conclusion
Treatment group produce effects 31 examples (51.67%), effective 18 examples (30%), invalid 11 examples (18.33%), total effective rate is 81.67%.Matched group produce effects 37 examples (61.67%), effective 14 examples (23.33%), invalid 9 examples (15%), total effective rate is 85%.Two groups of curative effect differences do not have significance meaning (Ridit analyzes, t=0.672, P＞0.05).
Many moving index total points, behavior total points (X ± s) relatively before and after the treatment of table 1 liang group
| Project | Group | ????n | Evaluation before the treatment | Treat evaluation at 12 weekends |
| Many moving index total points | The treatment group | ????60 | ????22.06±4.48 | ????10.22±4.85※△ |
| Matched group | ????60 | ????22.26±4.40 | ????10.04±6.20※ | |
| The behavior total points | The treatment group | ????60 | ????42.46±10.98 | ????16.22±11.6※△ |
| Matched group | ????60 | ????41.98±8.16 | ????14.86±11.67※ |
※ is relatively preceding with treatment, and (t check) P＜0.01 △ and matched group compare, (t check) P＞0.05.
3, treat side reaction generation at 12 weekends frequency relatively for two groups
Result of the test sees Table 2.
The table 2 liang main side reaction generation frequency in group treatment back (example (%))
| Side reaction | The treatment group | Matched group |
| Insomnia | ????9(18)※※ | ????38(76) |
| Cathisophobia | ????18(36) | ????21(42) |
| Xerostomia | ????6(12)※※ | ????48(96) |
| Blurred vision | ????2(4) | ????5(10) |
| Constipation | ????10(20)※※ | ????32(64) |
| Perspire | ????7(14)※ | ????18(36) |
| Feel sick | ????8(16)※※ | ????37(74) |
| Lose weight | ????7(14)※※ | ????45(90) |
| Loss of appetite or anorexia | ????11(22)※※ | ????50(100) |
Compare ※ P＜0.05, ※ ※ P＜0.01 (x with matched group
2Check)
4, reaching treatment before the clinical examination index treatment changes for 12 weekends
Soft neurosigns contrast sees Table 3 before and after (1) two group of treatment.
Soft neurosigns contrast (example (%)) before and after the table 3 liang group treatment
| Project | Group | Before the treatment | After the treatment |
| Turn over hands test (+) | The treatment group | ??32(64) | ????9(18)※ |
| Matched group | ??36(72) | ????11(22)※ | |
| To finger to finger test (+) | The treatment group | ??37(74) | ????8(16)※ |
| Matched group | ??34(69) | ????6(12)※ |
Relatively preceding with treatment, ※ P＜0.01 (x
2Check), comparing difference there are no significant meaning (P＞0.05) but between two groups.
Reach 2 inspections at 12 weekends routine blood test, liver function Non Apparent Abnormality before (2) two groups of treatments.
Six, discuss
Clinical trial shows that the curative effect and the methylphenidate of Drug therapy childhood hyperkinetic syndrome of the present invention are suitable, and two groups of total effective rates are respectively curative effect there was no significant difference between 81.67%, 85%, two group.It seems from Tess result, the methylphenidate group with obvious insomnia, xerostomia, constipation occur, feel sick, lose weight, loss of appetite or anorexia aspect symptom be for seeing more; And the medication therapy groups occurrence frequency of the present invention and the order of severity are than methylphenidate obviously less and gently.
Medicine of the present invention is a kind of active drug of treatment childhood hyperkinetic syndrome, and curative effect and methylphenidate are suitable, and side effect is little, can further test clinically.
Seven, model case
Case 1
Patient Lee, the man 6 years old, goes to a doctor in August, 2002.It is how moving, absent minded that mother patient chats the patient, undisciplined on class in the instruction that kindergarten can not be accepted teacher, can not keep in with other children, and school grade is poor, and language performance is clear and definite inadequately.Look into IQ 78, head CT inspection: cerebral dysplasia.Be diagnosed as childhood hyperkinetic syndrome.Oral medicament capsule of the present invention, each 4, every day 3 times.In January after taking medicine, patient's hyperkinetic syndrome shape promptly takes an evident turn for the better, and can peace and quiet sit down, and attention is more preceding to be concentrated.Continue to take medicine after March, patient's language performance before is clearly better, and last class hour is no longer naughty, can keep in with other children, and school grade is clearly better.
Case 2
Patient Zhang, the woman 7 years old, goes to a doctor in March, 2002.When the patient goes to a doctor,, bounce up and down, shout from stool stamping one's foot that clinic does not stop.Its mother chats the patient and can not quietly sit 10 minutes, and is absent minded, do not listen teacher's instruction on class, and school grade is poor, and intelligence is normal substantially.Check no abnormality seen through head CT.Be diagnosed as childhood hyperkinetic syndrome.Oral medicament capsule of the present invention, each 4, every day 3 times.Took medicine back 50 days, and examined once more, its mother tells patient's hyperkinetic syndrome shape and takes a turn for the better, and last class hour can listen to the teacher in peace and quiet.Continue to take medicament capsule of the present invention after 2 months, patient's hyperkinetic syndrome shape disappears, the school grade progress.Continue to take medicine February, to consolidate curative effect.
Case 3
Patient Chen, the woman 10 years old, goes to a doctor in April, 2002.It is how moving that its mother chats the patient, the dried something of can not focusing one's attention on, and last class hour always speaks up, and school grade is poor, and still in second grade at primary school, examination is all failed at every turn now, and looking into IQ is 76.Head CT is checked no abnormality seen.Be diagnosed as childhood hyperkinetic syndrome.Oral medicament capsule of the present invention, every day 3 times, each 5.Took medicine back 2 months, patient's hyperkinetic syndrome shape is clearly better, and last class hour can listen to the teacher in peace and quiet.Continue to take medicament capsule of the present invention after 2 months, patient's hyperkinetic syndrome shape disappears, and total marks of the examination can be passed.Continue to take medicine February, to consolidate curative effect.
Function of the present invention: tonifying YIN is calmed the nerves, and YANG hyperactivity suppressing relieves dizziness, high fever, infantile convulsions, epilepsy, etc.
The present invention cures mainly: hyperkinetic syndrome (attention deficit hyperactivity disorder).
Specification of the present invention: the heavy 5g of the every bag of powder of the present invention, every gram contains crude drug in whole 0.496g; Every heavy 0.4g of capsule of the present invention, every gram contains crude drug in whole 1.55g; Every heavy 0.4g, every gram contains crude drug in whole 1.24g.
Usage and dosage of the present invention: clothes were three times in one day, ante cibum or one after each meal, powder each clothes 1/2 bag below 2 years old, 2～3 years old each clothes 3/4 bag, 3～7 years old each clothes 1 bag, each clothes 1 bag more than 7 years old, 4 of 3,3～7 years old each clothes of 2,2～3 years old each clothes of capsule each clothes below 2 years old, 5～6 of each clothes more than 7 years old, 3 sheets of 2,2～3 years old each clothes of tablet each clothes below 2 years old, 4 of 3～7 years old each clothes, 5～6 of each clothes more than 7 years old.
Storage: airtight protection against the tide.
Effect duration of the present invention: 2 years.
Claims (4)
1, a kind of oral drugs for the treatment of childhood hyperkinetic syndrome is characterized in that it is by the following weight parts proportion raw material medicament of formulation method preparation routinely:
6～18 parts of Fructus Schisandrae Chinensis
5～30 parts of Semen Ziziphi Spinosaes
6～18 parts of the Radix Paeoniae Albas
5～15 parts in Rhizoma Gastrodiae
1～6 part of Cornu Bubali
6～15 parts of Radix Curcumaes
1～6 part in Radix Glycyrrhizae
2. according to the oral drugs of the described treatment childhood hyperkinetic syndrome of claim 1, wherein the weight proportion of each raw material is:
8～15 parts of Fructus Schisandrae Chinensis
10～25 parts of Semen Ziziphi Spinosaes
8～15 parts of the Radix Paeoniae Albas
5～12 parts in Rhizoma Gastrodiae
2～5 parts of Cornu Bubalis
8～12 parts of Radix Curcumaes
1～5 part in Radix Glycyrrhizae
3, according to the oral drugs of the described treatment childhood hyperkinetic syndrome of claim 1, wherein the weight proportion of each raw material is:
10 parts of Fructus Schisandrae Chinensis
15 parts of Semen Ziziphi Spinosaes
12 parts of the Radix Paeoniae Albas
8 parts in Rhizoma Gastrodiae
4 parts of Cornu Bubalis
10 parts of Radix Curcumaes
3 parts in Radix Glycyrrhizae
4. according to the oral drugs of claim 1 or 2 or 3 described treatment dementias, it is characterized in that: said medicament is the above powder or capsule or a tablet of galenic pharmacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310122223 CN1228079C (en) | 2003-12-29 | 2003-12-29 | Oral medicine for treating child restless syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310122223 CN1228079C (en) | 2003-12-29 | 2003-12-29 | Oral medicine for treating child restless syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1554426A true CN1554426A (en) | 2004-12-15 |
| CN1228079C CN1228079C (en) | 2005-11-23 |
Family
ID=34338639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310122223 Expired - Fee Related CN1228079C (en) | 2003-12-29 | 2003-12-29 | Oral medicine for treating child restless syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1228079C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524464A (en) * | 2014-12-30 | 2015-04-22 | 陈淑娟 | Traditional Chinese medicine preparation for treating hyperactivity and preparation method of traditional Chinese medicine preparation |
| CN104958709A (en) * | 2015-07-25 | 2015-10-07 | 徐显廷 | Traditional Chinese medicine oral liquid for treating children attention deficit hyperactivity disorder |
| CN109620932A (en) * | 2017-10-09 | 2019-04-16 | 范国华 | A kind of Chinese traditional treatment new method of children's hyperkinetic syndrome |
| CN112641912A (en) * | 2019-10-10 | 2021-04-13 | 王忠民 | Medicine for quickly treating attention deficit hyperactivity disorder |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100444883C (en) * | 2006-03-10 | 2008-12-24 | 陈德林 | Anshenjiannaocong granule and its compounding process |
-
2003
- 2003-12-29 CN CN 200310122223 patent/CN1228079C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524464A (en) * | 2014-12-30 | 2015-04-22 | 陈淑娟 | Traditional Chinese medicine preparation for treating hyperactivity and preparation method of traditional Chinese medicine preparation |
| CN104958709A (en) * | 2015-07-25 | 2015-10-07 | 徐显廷 | Traditional Chinese medicine oral liquid for treating children attention deficit hyperactivity disorder |
| CN109620932A (en) * | 2017-10-09 | 2019-04-16 | 范国华 | A kind of Chinese traditional treatment new method of children's hyperkinetic syndrome |
| CN112641912A (en) * | 2019-10-10 | 2021-04-13 | 王忠民 | Medicine for quickly treating attention deficit hyperactivity disorder |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1228079C (en) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1211107C (en) | Mixture for improving blood circulation | |
| CN1299694C (en) | Flavone composition for sobering and liver protection and its use | |
| CN1228079C (en) | Oral medicine for treating child restless syndrome | |
| CN1814216A (en) | Chinese medicine composition for diminishing speckle and pox | |
| CN100346817C (en) | Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia | |
| CN1813819A (en) | Hedgehog hydnum fruiting body or hyphostroma and culture extract and formulation and preparing method | |
| CN101041024A (en) | Medicinal composition for treating tuberculosis and its preparing process | |
| CN1785307A (en) | Chinese medicine for treating mammary gland cystoma, mammitis and preparation method of its film coating | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1628662A (en) | Medicine with abirritation | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1857495A (en) | Compound chinese preparation for treating pain symptom and its preparing process | |
| CN1293983A (en) | Hypolipemic medicine and its preparing process and application | |
| CN1166402C (en) | Composite Chinese medicine with health care function | |
| CN1066959C (en) | Medicine for treating hydrocephalus | |
| CN1211111C (en) | Antilipemic Chinese medicine | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1186026C (en) | Application of hydroxyethyl puerarin in preparation of new medicine for curing cerebrovascular diseases | |
| CN1030275C (en) | Nutrient health composition for middle-aged and old people | |
| CN1634293A (en) | 'Xianlinggubao' new preparation, its preparing method and application | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN1239192C (en) | Chinese medicine composition for treating fang deficiency of epigastric pain and preparing method thereof | |
| CN1739669A (en) | Prepn process of Chinese medicine and its coated tablet for treating cystic mastoproliferation and mastitis | |
| CN1583014A (en) | Composite Chinese medicine for non-insulin dependent diabete and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |